- Home
- CTNM vs EICC Comparison
CTNM vs EICC Comparison
Compare CTNM & EICC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CTNM | EICC |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.1M | N/A |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | CTNM | EICC |
|---|---|---|
| Price | $11.51 | $25.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 244.6K | 18.7K |
| Earning Date | 10-30-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.96% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $51,224,692.00 |
| Revenue This Year | N/A | $39.61 |
| Revenue Next Year | N/A | $27.28 |
| P/E Ratio | ★ N/A | $23.44 |
| Revenue Growth | N/A | ★ 68.61 |
| 52 Week Low | $3.35 | $23.75 |
| 52 Week High | $15.25 | $25.25 |
Technical Indicators
Market Signals| Indicator | CTNM | EICC |
|---|---|---|
| Relative Strength Index (RSI) | 50.46 | 46.11 |
| Support Level | $10.42 | $25.08 |
| Resistance Level | $13.48 | $25.35 |
| Average True Range (ATR) | 0.73 | 0.09 |
| MACD | 0.13 | -0.02 |
| Stochastic Oscillator | 39.91 | 32.44 |
Price Performance
Historical ComparisonAbout CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About EICC Eagle Point Income Company Inc. 8.00% Series C Term Preferred Stock due 2029
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.